<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822546</url>
  </required_header>
  <id_info>
    <org_study_id>FON-01blu-2018</org_study_id>
    <nct_id>NCT03822546</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetic Profiles of Cigarettes and E-Cigarettes With Nicotine Salt Formulations</brief_title>
  <official_title>A Randomized, Open-label, Cross-over Clinical Study to Evaluate the Pharmacokinetic Profiles of Cigarettes and E-Cigarettes With Nicotine Salt Formulations in Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fontem Ventures BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fontem Ventures BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the pharmacokinetic profiles and subjective effects of nicotine from two
      e-cigarette device platforms with varying concentrations of nicotine lactate (nicotine salt)
      e-liquid relative to conventional cigarettes. It was designed as a randomized, open-label,
      cross-over clinical study conducted in 15 healthy US adult smokers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nicotine pharmacokinetics Cmax</measure>
    <time_frame>30 minutes following the start of product use (12 measurements over the period)</time_frame>
    <description>Mean maximum plasma nicotine concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nicotine pharmacokinetics Tmax</measure>
    <time_frame>30 minutes following the start of product use (12 measurements over the period)</time_frame>
    <description>Median time to maximum plasma nicotine concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nicotine pharmacokinetics AUC0-30</measure>
    <time_frame>30 minutes following the start of product use (12 measurements over the period)</time_frame>
    <description>Mean area under the plasma nicotine concertation-time curve, from time zero to 30 minutes (AUC0-30)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective effects questionnaire</measure>
    <time_frame>20 minutes after the start of product use</time_frame>
    <description>Likert-type scale with responses ranging from 1 (not at all) to 7 (extremely). The following questions were asked: Did it make you dizzy? Did it make you nauseous? Did you enjoy it? Did it relieve the urge to smoke? Was it enough nicotine? Was it too much nicotine?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and nature of any adverse events (AE)</measure>
    <time_frame>Through study completion, 6 days</time_frame>
    <description>Incidence and nature of any adverse events (AE) (Safety and Tolerability)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Conventional cigarette</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject's preferred brand of commercially available conventional cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu 25 mg freebase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>myblu pod-system containing 25 mg nicotine ('freebase') tobacco flavour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu 16 mg nicotine salt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>myblu pod-system containing 16 mg nicotine salt tobacco flavour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu 25 mg nicotine salt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>myblu pod-system containing 25 mg nicotine salt tobacco flavour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myblu 40 mg nicotine salt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>myblu pod-system containing 40 mg nicotine salt tobacco flavour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blu PRO 48 mg nicotine salt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>blu PRO open-system containing 48 mg nicotine salt tobacco flavour</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional cigarette</intervention_name>
    <description>Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals</description>
    <arm_group_label>Conventional cigarette</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu 25 mg freebase</intervention_name>
    <description>E-cigarette used for 10 inhalations every 30 seconds</description>
    <arm_group_label>myblu 25 mg freebase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu 16 mg nicotine salt</intervention_name>
    <description>E-cigarette used for 10 inhalations every 30 seconds</description>
    <arm_group_label>myblu 16 mg nicotine salt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu 25 mg nicotine salt</intervention_name>
    <description>E-cigarette used for 10 inhalations every 30 seconds</description>
    <arm_group_label>myblu 25 mg nicotine salt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myblu 40 mg nicotine salt</intervention_name>
    <description>E-cigarette used for 10 inhalations every 30 seconds</description>
    <arm_group_label>myblu 40 mg nicotine salt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blu PRO 48 mg nicotine salt</intervention_name>
    <description>E-cigarette used for 10 inhalations every 30 seconds</description>
    <arm_group_label>blu PRO 48 mg nicotine salt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having smoked ≥10 manufactured cigarettes per day for at least the last year

          -  Expired carbon monoxide level of &gt;10 ppm at screening

          -  Tested positive for urinary cotinine (≥500 ng/mL)

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to any component of the e-liquid formulations

          -  Taking or receiving prescription smoking cessation medicines

          -  Willing or considering to stop smoking

          -  Smokers who draw smoke into their mouth and throat but do not inhale

          -  Relevant illness history

          -  Body mass index (BMI) of less than 18 kg/m2 or greater than 40 kg/m2

          -  Breastfeeding women

          -  Women of child-bearing potential who were not using an accepted method of
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

